Purchase Order 75N93022P01218

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,460 firm fixed-price purchase order to Psomagen Inc. for COVID-19 RNA isolation, DNA generation, and library preparation services under the FY26 Unlisted Data Objective (UDO) Initiative. The contract, awarded on September 20, 2022, with an ultimate completion date of September 18, 2023, was performed at Psomagen's facility in Rockville, Maryland. No set-aside designation was applied to this procurement. Psomagen, a...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Psomagen Inc. for $17,004.00 on April 8, 2024, for library preparation and sequencing services, with ultimate completion by June 7, 2024. Work is performed in Rockville, Maryland. No set-aside was used. The order is priced on a firm fixed-price basis.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Psomagen Inc. for RNA sequencing services on August 8, 2022, with a ceiling value of $23,750.00. Work is performed in Rockville, Maryland. The purchase order is firm fixed price with ultimate completion scheduled for September 16, 2022. No set-aside category applied to this award.</p>

The National Institute of Allergy and Infectious Diseases awarded a $17,810 firm fixed price purchase order to Psomagen Inc. on September 13, 2021, with an ultimate completion date of August 4, 2022. This contract action was undertaken to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), in preparation for the September 30, 2026 closing of the period of availability for these fiscal year funds. The work was performed in...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Illumina, Inc. valued at $189,332.08 on July 5, 2022 for a service agreement covering multiple Illumina DNA sequencers. The order is firm fixed-price with no set-aside designation. Performance takes place in Bethesda, Maryland. The purchase order was issued under a solicitation posted June 16, 2022 with a due date of June 27, 2022, and carries an ultimate completion date of July 4, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to the State of Maryland for $25,925.00 on September 18, 2015, for genomic libraries for whole-genome sequencing and ChIP-seq applications. Work is performed in Bethesda, Maryland. The order carries a firm fixed-price structure with an ultimate completion date of February 10, 2017. No small business set-aside applies.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Illumina, Inc. for $32,657.69 on November 1, 2024, covering an Illumina NextSeq 2000 Silver Support Plan. The order represents a modification to de-obligate excess funds from the FY 2026 UDO Initiative. No set-aside was used. Performance occurs at Bethesda, Maryland. The purchase order is firm fixed-price with an ultimate completion date of May 18, 2026.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Geneuniversity Inc. for custom DNA services on August 7, 2020, with a ceiling value of $10,435.00 and firm fixed-price terms. The order was issued under quote no. 1007569 (LAW2034981) with an ultimate completion date of September 5, 2020. Performance occurs at the awardee's facility in Newark, Delaware.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Illumina, Inc. for sequencing kits valued at $19,072.05, with an award date of April 13, 2021 and completion date of May 12, 2021. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $14,756.36 on September 13, 2021, for sequencing services under the FY26 UDO Initiative. Performance is at Genscript's facility in Piscataway, New Jersey. The order carries a firm fixed price and was completed by December 31, 2021.</p>